Open AccessEstablishment of biological and pharmacokinetic assays of telomerase‐specific replication‐selective adenovirus
Author(s) -
Hashimoto Yuuri,
Watanabe Yuichi,
Shirakiya Yoshiko,
Uno Futoshi,
Kagawa Shunsuke,
Kawamura Hitoshi,
Nagai Katsuyuki,
Tanaka Noriaki,
Kumon Horomi,
Urata Yasuo,
Fujiwara Toshiyoshi
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2007.00665.x
Subject(s) - telomerase , microbiology and biotechnology , telomerase reverse transcriptase , biology , internal ribosome entry site , reverse transcriptase , real time polymerase chain reaction , multiplicity of infection , virology , polymerase chain reaction , cancer research , virus , ribosome , gene , rna , biochemistry
The use of replication‐selective tumor‐specific viruses represents a novel approach for the treatment of neoplastic disease. We constructed an attenuated adenovirus, telomerase‐specific replication‐selective adenovirus (TRAD), in which the human telomerase reverse transcriptase promoter element drives the expression of the E1A and E1B genes linked with an internal ribosome entry site (IRES). Forty‐eight hours after TRAD infection at a multiplicity of infection of 1.0, the cell viability of H1299 human lung cancer cells was consistently less than 50% and therefore this procedure could be used as a potency assay to assess the biological activity of TRAD. We also established a quantitative real‐time polymerase chain reaction (PCR) analysis with consensus primers for either the adenovirus E1A or IRES sequence. The linear ranges of quantitation with E1A and IRES primers were 10 3 –10 8 and 10 2 –10 8 plaque‐forming units/mL in the plasma, respectively. The PCR analysis demonstrated that the levels of E1A in normal tissues were more than 10 3 lower than in the tumors of A549 human lung tumor xenografts in nu/nµ mice at 28 days after intratumoral injection. Our results suggest that the cell‐killing assay against H1299 cells and real‐time PCR can be used to assess the biological activity and biodistribution of TRAD in clinical trials. ( Cancer Sci 2008; 99: 385–390)